Basic Clarithromycin Information

• INN (International Nonproprietary Name): Clarithromycin (INN-latin: Clarithromycinum).
• Brand Names Available In United Kingdom: Klaricid; Klaricid XL; generic clarithromycin from Sandoz, Ranbaxy and other suppliers.
• ATC Code: J01FA09.
• Forms & Dosages: Film-coated tablets 250 mg and 500 mg; extended-release 500 mg tablets; powder/granules for oral suspension 125 mg/5 mL and 250 mg/5 mL; paediatric suspension formulations 125 mg/5 mL and 250 mg/5 mL.
• Manufacturers In United Kingdom: Branded and generic supplies in the UK market include products from Abbott/AbbVie (Klaricid), Sandoz and Ranbaxy among other generic manufacturers.
• Registration Status In United Kingdom: MHRA registered; prescription-only medicine.
• OTC / Rx Classification: Prescription-only (Rx).

Key Findings From Recent Trials

Major 2022–2024 Study Trends

Clinicians are worried about rising clarithromycin resistance and its impact on outcomes.

Multiple systematic reviews and pooled analyses up to 2024 show that clarithromycin resistance reduces effectiveness of standard triple therapy for Helicobacter pylori.

Macrolide resistance in common respiratory pathogens such as Streptococcus pneumoniae and Haemophilus influenzae has also increased in many regions.

Where local clarithromycin resistance exceeds roughly 15–20%, eradication rates for clarithromycin-based triple regimens fall below acceptable thresholds.

Guidance increasingly recommends either alternative empiric regimens or susceptibility-guided therapy for H. pylori in areas with high macrolide use.

Main Outcomes

Randomised trials still show acceptable short-course tolerability for clarithromycin, but clinical effectiveness for H. pylori has declined where resistance is common.

Comparative analyses indicate clarithromycin can remain useful for skin and soft-tissue infections and for some mycobacterial regimens when susceptibility is confirmed.

For community respiratory infections, alternatives such as doxycycline or amoxicillin are favoured where local macrolide resistance is high.

Safety Observations

Observational cohorts and pooled safety data highlight QT prolongation as a key safety signal in susceptible patients.

Drug–drug interactions via CYP3A4 inhibition are frequently reported and can produce clinically significant events.

Rare hepatotoxicity and cholestatic jaundice linked to clarithromycin have been described; caution is advised in people with prior hepatic reactions.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask, “How does clarithromycin work?”

Clarithromycin is a macrolide antibiotic that stops bacteria making essential proteins, which prevents bacterial growth and allows the immune system to clear the infection.

It is commonly given as an oral tablet or suspension for chest infections, skin infections and as part of combination H. pylori therapy.

Scientific Breakdown

Clarithromycin (INN: clarithromycin; ATC: J01FA09) binds to the 50S ribosomal subunit and blocks peptide chain elongation.

The drug is primarily bacteriostatic at therapeutic concentrations, though bactericidal activity can occur at higher concentrations for select pathogens.

Clarithromycin concentrates intracellularly, achieving high levels in respiratory tissues and macrophages, which helps treat intracellular organisms and atypical pathogens.

It is metabolised hepatically with important CYP3A4 interactions, and active metabolites extend its half-life.

Renal impairment and severe hepatic dysfunction affect dosing choices; extended-release forms should be avoided in severe hepatic impairment.

The pharmacodynamic profile is time-dependent inhibition with sustained tissue levels, explaining usual twice-daily dosing and the availability of 500 mg modified-release preparations.

Scope Of Approved & Off-Label Use

United Kingdom Approvals

Clarithromycin is MHRA-registered in the UK and is a prescription-only medicine.

Licensed indications historically include community-acquired respiratory tract infections, skin and soft-tissue infections, and use as part of combination regimens for H. pylori eradication.

Standard adult dosing on licensed products is 250–500 mg every 12 hours, with paediatric suspensions available in 125 mg/5 mL and 250 mg/5 mL strengths.

Notable Off-Label Trends

Clinicians may prescribe clarithromycin off-label for atypical mycobacterial infections, frequently as part of combination regimens with ethambutol or other agents.

Occasional use in ENT and dermatology is seen when first-line agents are unsuitable or when susceptibility testing supports use.

Increasing clarithromycin resistance has narrowed empiric utility for H. pylori in many areas, prompting a shift to bismuth quadruple or susceptibility-guided therapy.

Dosage Strategy

General Dosing

Adults typically receive 250–500 mg orally every 12 hours depending on indication and formulation.

Extended-release 500 mg tablets provide a once- or twice-daily option for selected products and patient preferences.

Paediatric dosing is weight-based at approximately 7.5 mg/kg twice daily with a maximum of 500 mg per dose, and oral suspensions are commonly used for children.

For creatinine clearance under 30 mL/min, reduce the dose by about 50%.

Avoid extended-release products in severe hepatic impairment.

Condition-Specific Dosing

Respiratory And Skin Infections

Typical regimens are 250–500 mg every 12 hours for 5–14 days, adjusted by clinical response and severity.

H. Pylori (Combination)

When clarithromycin is used as part of triple therapy it is usually given as 500 mg twice daily, with total duration commonly 7–14 days depending on the chosen eradication protocol.

Mycobacterial Infections

For many atypical mycobacterial infections, clarithromycin is prescribed at 500 mg twice daily, often for months depending on organism and clinical response.

Safety Protocols

Contraindications

Absolute contraindications include known hypersensitivity to macrolides and history of cholestatic jaundice or hepatic dysfunction attributed to clarithromycin.

Do not co-prescribe clarithromycin with drugs contraindicated due to CYP3A4 interactions such as cisapride, pimozide and ergot derivatives.

Relative contraindications include moderate–severe hepatic or renal impairment, pregnancy (particularly in the first trimester) and breastfeeding without specialist advice.

Adverse Effects

Common mild to moderate adverse effects are gastrointestinal upset, metallic taste, headache and reversible elevations in liver enzymes.

Serious but rare events include cholestatic hepatitis, QT prolongation and arrhythmias, and severe hypersensitivity reactions.

Drug interactions via CYP3A4 can precipitate events such as statin-associated myopathy when co-administered with simvastatin or lovastatin.

Monitoring with liver function tests should be considered for prolonged therapy or prior hepatic disease, and an ECG can be appropriate for patients with cardiac risk factors or concurrent QT-prolonging drugs.

Interaction Mapping

Food Interactions

Absorption of many clarithromycin tablets is not markedly affected by food though some extended-release products have product-specific instructions and should be taken per the SPC.

Reconstituted suspensions are generally stable with or without food for paediatric dosing but follow product labelling for exact guidance.

Drug Combinations To Avoid

CYP3A4-Mediated Risks

Clarithromycin is a moderate inhibitor of CYP3A4 and may increase plasma concentrations of drugs metabolised by this enzyme.

Avoid or adjust drugs with narrow therapeutic windows such as certain antiarrhythmics, pimozide, cisapride and ergot derivatives.

QT-Prolonging Combinations

Do not combine clarithromycin with other QT-prolonging agents without ECG monitoring and specialist advice.

Other Important Interactions

Warfarin requires INR monitoring when co-administered with clarithromycin.

Immunosuppressants such as tacrolimus, certain benzodiazepines and some antiepileptics need dose review and monitoring if given alongside clarithromycin.

Always check the local product SPC and consult a pharmacist when polypharmacy is present.

Patient Experience Analysis

Survey Data

Real-world outpatient surveys and pharmacovigilance reports describe good tolerability for short courses of clarithromycin.

Most patients report mild gastrointestinal symptoms and altered taste, and discontinuation rates for short courses remain low.

Adherence is affected by twice-daily dosing compared with once-daily competitors such as azithromycin.

Paediatric adherence depends on suspension palatability and dosing volume; availability of 125 mg/5 mL and 250 mg/5 mL suspensions supports paediatric use.

Forum Trends

Patients commonly raise concerns about drug interactions with statins and cardiac medications, and about decreasing usefulness for H. pylori due to resistance.

Reports of prolonged metallic taste appear in a small proportion of users on forums and patient groups.

Pharmacists should advise patients about likely side effects, the importance of completing prescribed courses, and when to seek urgent review for severe reactions.

Distribution & Pricing Landscape

Clarithromycin is widely available in the UK as branded products (Klaricid, Klaricid XL) and multiple generics supplied through NHS channels and community pharmacies.

Major manufacturers and generic producers include Abbott/AbbVie, Sandoz and Ranbaxy among others.

Generic competition since patent expiry has lowered prices, though branded extended-release formulations remain relatively more expensive.

For NHS prescribing the cost-effectiveness of choosing clarithromycin depends on likely effectiveness given local resistance patterns.

Supply fluctuations occasionally affect availability; pharmacy teams should monitor national drug shortage alerts and local stock.

Alternative Options

Comparison Summary

Azithromycin offers once-daily dosing and is often favoured for adherence, with fewer CYP3A4 interactions, but resistance trends vary by region.

Erythromycin is associated with greater gastrointestinal adverse effects and more frequent dosing.

Non-macrolide alternatives include doxycycline for respiratory and some skin infections, and amoxicillin where organisms are susceptible.

For H. pylori where clarithromycin resistance is high, bismuth quadruple therapy is a recommended alternative.

Pros And Cons

Clarithromycin Pros: Good tissue penetration, established dosing schedules and paediatric suspension options.

Clarithromycin Cons: CYP3A4 interactions, QT prolongation risk and reduced empirical efficacy for H. pylori in settings with significant macrolide resistance.

Clinical choice should follow pathogen, susceptibility data, interaction risk, comorbidity and likely adherence, guided by local antimicrobial stewardship and microbiology advice.

Regulatory Status

International Registration

Clarithromycin is registered worldwide and classified under WHO/ATC code J01FA09.

Patent expiry around 2005 led to broad generic availability internationally.

UK-Specific Notes

The MHRA registers clarithromycin products in the UK; commonly available UK brands include Klaricid and Klaricid XL in addition to generics.

Clarithromycin remains a prescription-only medicine and prescribers should follow SPC guidance for contraindications, dose adjustments and monitoring.

NICE and local stewardship policies increasingly recommend testing for clarithromycin resistance or using alternative regimens for H. pylori where resistance prevalence is high.

Consolidated FAQ

Q: Is clarithromycin still suitable empirically for H. pylori?

A: Only when local clarithromycin resistance is low or susceptibility testing confirms activity; otherwise use bismuth quadruple therapy or alternative regimens.

Q: Can patients on statins take clarithromycin?

A: Avoid simvastatin and lovastatin with clarithromycin due to CYP3A4 inhibition; consider alternative statins such as pravastatin or pause statin therapy after specialist advice.

Q: How to dose in renal impairment?

A: Reduce the clarithromycin dose by 50% if creatinine clearance is below 30 mL/min and avoid extended-release forms in severe hepatic impairment.

Q: Paediatric use?

A: Use suspension formulations (125 mg/5 mL or 250 mg/5 mL) with weight-based dosing around 7.5 mg/kg twice daily, up to 500 mg per dose.

Q: Storage guidance?

A: Store film-coated tablets in a dry place below 25°C and reconstituted suspension at or below room temperature; use reconstituted suspension within 14 days and do not freeze.

Visual Guide

Dosage Flowchart (Text Form)

Step 1: Identify indication (respiratory, skin, H. pylori, mycobacterial).

Step 2: Check local resistance/susceptibility for H. pylori and respiratory pathogens.

Step 3: Review comorbidities (hepatic/renal, cardiac QT risk) and current medications for CYP3A4 interactions.

Step 4: Select formulation: tablets 250/500 mg, extended-release 500 mg, suspension 125/250 mg per 5 mL for children.

Step 5: Prescribe dose: adults 250–500 mg twice daily; H. pylori 500 mg twice daily as part of combination; paediatric 7.5 mg/kg twice daily.

Side-Effect Risk Matrix

Low Risk: Short course in otherwise healthy adult — expect possible mild GI upset or altered taste.

Moderate Risk: Older adults or those on multiple medicines — interaction screening and liver monitoring advised.

High Risk: Known QT prolongation, strong CYP3A4 co-medications or prior hepatic reaction — avoid clarithromycin and choose alternatives.

Storage & Transport

Pharmacy Handling

Store film-coated tablets in a dry place below 25°C and protect from light and moisture according to the product SPC.

Extended-release and suspension product SPCs may carry specific storage instructions; maintain ambient conditions during distribution unless stated otherwise.

Patient Instructions

Tablets

Keep tablets in the original pack and store below 25°C, away from humidity and out of reach of children.

Reconstituted Suspension

After mixing, store the suspension at or below room temperature and use within 14 days; do not freeze.

Shake well before use and measure doses with a calibrated spoon or oral syringe.

Return unused antibiotics to the pharmacy for safe disposal.

Guidelines For Proper Use

Prescriber Checklist

Confirm indication and whether clarithromycin is appropriate given local resistance data.

Check allergies and prior macrolide adverse reactions.

Review concurrent medications for CYP3A4 substrates and QT-prolonging agents.

Adjust dose for renal impairment and avoid extended-release forms in severe hepatic disease.

Choose the formulation that best supports adherence for the patient (tablet or suspension).

Stewardship & Monitoring

Prefer susceptibility-guided therapy for H. pylori and avoid clarithromycin when local resistance suggests likely failure.

Limit duration to recommended courses to reduce selective pressure for resistance.

Monitor liver function for prolonged courses or prior hepatic disease and consider ECG monitoring in patients with cardiac risk factors.

Provide clear counselling on interactions with statins, anticoagulants and immunosuppressants.

Concluding Notes On Access

Patients often ask if clarithromycin can be bought online.

Clarithromycin is a prescription-only medicine in the United Kingdom, and pharmacists must follow MHRA and NHS requirements for supply.

Some licensed online pharmacies provide private prescriptions or pharmacist-led consultations to supply clarithromycin legally and discreetly, with typical delivery times to United Kingdom addresses in 5–14 days.

Delivery Across United Kingdom

Final Prescriber Checklist

Confirm local resistance data before using clarithromycin empirically for H. pylori or community pneumonias.

Screen for macrolide allergy, hepatic history and cardiac risk factors including QT prolongation.

Review full medication lists for CYP3A4 substrates and ensure monitoring where necessary.

Adjust doses in renal impairment and choose appropriate formulations for paediatric patients.

Document counselling on expected adverse effects, interactions and storage instructions.

Summary

Clarithromycin remains a useful macrolide antibiotic with strong tissue penetration and established paediatric suspensions and adult formulations.

Rising clarithromycin resistance, especially for H. pylori and some respiratory pathogens, has changed empiric use in many settings and puts a premium on local susceptibility data and stewardship.

Safety considerations focus on hepatic monitoring, QT-prolongation risk and CYP3A4-mediated interactions.

Where clarithromycin is chosen, follow SPC dosing, adjust for renal and hepatic impairment and counsel patients clearly on likely side effects and interactions.